CRIS

Permanent URI for this communityhttps://scripta.up.edu.mx/handle/20.500.12552/1

Browse

Settings

Access type: UnknownSubject: search.filters.subject.Metabolic control

Search Results

Now showing 1 - 2 of 2
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Risk Factors Associated with Diabetic Retinopathy with and without Macular Edema in Recently Diagnosed Patients with Type 2 Diabetes
    (Taylor and Francis Group, 2024)
    García-Ulloa, Ana
    ;
    Pérez-Peralta, Liliana
    ;
    Jaime-Casas, Salvador
    ;
    Jiménez-Corona, Aida
    ;
    Rivera-De La Parra, David
    Purpose: To evaluate the risk factors associated with diabetic macular edema (DME) in patients with a recent type 2 diabetes mellitus (T2DM) diagnosis. Patients and Methods: We conducted a case-control study at a third-level hospital in Mexico City. We enrolled patients ≥18 years old, with T2DM less than five years of diagnosis, without disabling complications, and non-smokers. The control group was patients with diabetic retinopathy and without macular edema (DR-DME). Cases were patients with DR+DME. We measured fasting glucose, creatinine, lipid profile, urinary albumin/creatinine ratio (ACR), and HbA1c. An ophthalmological examination consisted of visual acuity measurement, digital three-field fundus photography with an automatic non-mydriatic camera, slit lamp, and Optical coherence tomography (OCT) examination ©Dove Press
      14  2
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    De-escalating treatment indications for patients who achieve metabolic goals
    (Elsevier, 2024)
    García-Ulloa, Ana Cristina
    ;
    Jaime-Casas, Salvador
    ;
    Rosado-Lozoya, Johanna S.
    ;
    Serrano-Pérez, Nancy H.
    ;
    Hernández-Juárez, Diana
    Introduction: Robust evidence exists regarding initiation, intensification or modification of treatments. Recommendations to de-escalate therapy are lacking, specifically in diabetes. A successful treatment de-intensification reduces overtreatment, polypharmacy, and risk of adverse effects. Objective: To encompass current recommendations for deprescribing common drugs and create a consensus among health professionals. Methods: We reviewed four databases for deprescribing approaches published between 2010 and 2022. Articles were divided into different groups of drugs (for uric-acid, hypoglycemic, lipid-lowering, and psychotropic drugs).©Elsevier
      16  1